| FORM | 4 |
|------|---|
|------|---|

| Check this box if no |
|-----------------------|
| longer subject to |
| Section 16. Form 4 or |
| Form 5 obligations |
| may continue. See |
| Instruction 1(b). |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Response | es) | | | | | | | | | | |
|---|--|--|--------------------|-----------------------------------|----|---|---------------|---|--------------------|--|--|
| 1. Name and Address of STEIN EVAN A. | 2. Issuer Name an CymaBay Therap | | | 0.2 | ol | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X. Director 10% Owner | | | | | |
| (Last) C/O CYMABAY T GATEWAY BLVD | C DIC FOOD | 3. Date of Earliest Transaction (Month/Day/Year) 04/26/2016 | | | | | | | ther (specify belo | ow) | |
| NEWARK, CA 945 | | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person | | | |
| (City) | | | | | | | Acqu | ired, Disposed of, or Beneficially Ow | vned | | |
| 1.Title of Security (Instr. 3) | | 2. Transaction Date (Month/Day/Year) | Execution Date, if | 3. Transact Code (Instr. 8) | - | (A) or Disposed of (D) | | of (D) | 0 1 | Ownership | 7. Nature of Indirect Beneficial |
| | | | (Month/Day/Year) | Code | v | Amount | (A) or (D) | Price | X / | Direct (D) or Indirect (I) (Instr. 4) | Ownership (Instr. 4) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

| (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
|--|-------------|------------------|--------------------|------------|------|-----------------------------------|------|--------------|------------|-------------------|------------------|----------------|--------------|------------|------------|
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | | 5. Number 6. Date Exercisable and | | 7. Title and | | 8. Price of | 9. Number of | 10. | 11. Nature | | |
| Derivative | Conversion | Date | Execution Date, if | Transact | tion | of Expiration Date | | Amount of De | | Derivative | Derivative | Ownership | of Indirect | | |
| Security | or Exercise | (Month/Day/Year) | any | Code | | Derivati | ve | (Month/Day | /Year) | Underlying Securi | | Security | Securities | Form of | Beneficial |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) |) | Securitie | es | | | Securities (Ins | | (Instr. 5) | Beneficially | Derivative | Ownership |
| | Derivative | | | | | Acquire | d | (Inst | | (Instr. 3 an | (Instr. 3 and 4) | | | 2 | (Instr. 4) |
| | Security | | | | | (A) or | | | | | 0 | Direct (D) | | | |
| | | | | | | Dispose | d of | | | | | 1 | or Indirect | | |
| | | | | | | (D) | | | | | | Transaction(s) | · / | | |
| | | | | | | (Instr. 3, and 5) | 4, | | | | (Instr. 4) | (Instr. 4) | | | |
| | | | | | | and 5) | r – | | | | | | | | |
| | | | | | | | | | | | Amount | | | | |
| | | | | | | | | Date | Expiration | T: 4 | or | | | | |
| | | | | | | | | Exercisable | Date | Title | Number of | | | | |
| | | | | Code | v | (A) | (D) | | | | Shares | | | | |
| | | | | Couc | v | (A) | (D) | | | | Shares | | | | |
| Stock | | | | | | | | | | | | | | | |
| Option | \$ 2.81 | 04/26/2016 | | А | | 18,000 | | (1) | 04/25/2026 | Common Stock | 18 000 | \$ 0 | 18,000 | D | |
| (right to | φ 2.01 | 07/20/2010 | | 71 | | 10,000 | | | 04/25/2020 | Stock | 10,000 | ψŪ | 10,000 | D | |
| buy) | | | | | | | | | | | | | | | |

Reporting Owners

| | Relationships | | | | | | | |
|--|---------------|-----------|---------|-------|--|--|--|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | | | |
| STEIN EVAN A. C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BLVD., SUITE 130 NEWARK, CA 94560 | Х | | | | | | | |

Signatures

| /s/ Sujal Shah, by power of attorney | 04/27/2016 |
|--------------------------------------|------------|
| **Signature of Reporting Person | Date |

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares subject to the option are early exercisable. The option vests in 12 equal monthly installments with the vesting start date of April 1, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.